Back to Archived News
PURE Bioscience Granted US Patent on 14 New Ionic Silver/Organic Acid Complexes
Wednesday, August 29, 2007
New Patent Significantly Expands PURE’s IP Portfolio and Further Protects SDC
San Diego, CA -- PURE Bioscience (OTCBB:PURE) today announced that the United States Patent and Trademark Office issued patent number 7,261,905 on August 28, 2007, which covers PURE’s process of manufacturing complexes of electrolytically generated stabilized ionic silver with other organic acids, specifically identifying 14 new complexes. The new patent expands the scope of protection of PURE’s core technology patent, US Patent 6,197,814, for the composition and method of making of PURE’s silver dihydrogen citrate (SDC) antimicrobial.
Michael L. Krall, President and CEO of PURE Bioscience, stated, "In addition to strengthening the protection of our core technology, this new patent significantly expands our intellectual property portfolio. The characteristics and structures of the new molecules resemble those of our previously patented and commercialized SDC technology."
Krall continued, "Although we are absolutely focused on the current commercialization of SDC, there are potential applications for stabilized ionic silver in which the citric acid complex may not be the best fit. Our development objective is to identify which of the new complexes potentially increases flexibility in formulation, compatibility, production and end uses of stabilized ionic silver as an antimicrobial, and to continue development and/or licensing activity of those technologies determined to be commercially viable."
PURE has three previously granted US patents related to the SDC technology: US Patent 6,197,814 (2001) for the SDC disinfectant and method of its making, Patent 6,583,176 (2003) covering the combination of SDC and alcohol as a disinfectant, and Patent 6,890,953 (2005) covering a process for treating water with SDC. PURE also has several related patent applications pending on SDC in the US, including coverage of SDC in medical, personal care and preservative applications, the anhydrous – or crystalline – form of SDC, and SDC in combination with traditional chemical disinfectants. In addition, patents have issued or are pending for PURE’s SDC technology in approximately 70 countries.
The inventors of PURE’s new patented technology are Andrew B. Arata, President of ETI-H2O, a wholly owned subsidiary of PURE Bioscience, and Michael L. Krall. Arata is also the inventor of PURE’s original SDC technology.
About PURE Bioscience
PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented silver dihydrogen citrate (SDC) is an electrolytically generated source of stabilized ionic silver. SDC is colorless, odorless, tasteless, non-toxic, non-caustic and formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. SDC also offers 24-hour residual protection against standard indicator bacteria. PURE Bioscience, headquartered in El Cajon, California (San Diego metropolitan area), was incorporated in 1992. Additional information on PURE Bioscience is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Back to Archived News